Background: An accurate HPLC-fluorescence method for the simultaneous determination
of abiraterone acetate (prodrug) and abiraterone (drug) employed in the treatment of prostate cancer,
in urine and serum samples of men treated with this prodrug has been proposed.
Methods: The developed HPLC-FLD procedure permits the quantification of ABR and AA minimizing
laborious and complicated sample preparation procedures. The selectivity of the fluorescence detector
avoids the presence of endogenous and exogenous interfering compounds and has enough sensibility
for this determination.
Results: The method was applied for the analysis of human urines samples of five men and serum
samples of two men under treatment of prostate cancer. The excretion urinary in a patient was done
during 24 hours. The maximum abiraterone concentration for this patient was 27 ng/mL.
Conclusion: This method shows the advantage of being suitable for the analysis of urine and serum
samples of patients with prostate cancer who received daily doses of Zytiga.